-
The global ophthalmic drug track competition has opened, and domestic pharmaceutical companies are increasing their layout
Time of Update: 2023-02-02
acquisition On January 9, Puri Eye announced that Dongguan Guangming Eye Hospital recently obtained the business license and "Registration Notice" issued by the Dongguan Market Supervision Administration, and the acquisition of 35% of the equity of Dongguan Guangming Eye Hospital by Chuangfa Enterprise has completed the registration procedures for industrial and commercial changes.
-
Since December, many pharmaceutical companies have encountered setbacks in drug research and development
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];On December 19, AstraZeneca announced that the drug Imfinzi, as a monotherapy for patients with advanced non-small cell lung cancer, failed to achieve its primary goal of improving overall survival compared to platinum-based chemotherapy.
-
Bioengineered synthetic gene circuitry enhances cancer immunotherapy
Time of Update: 2022-12-30
In two separate studies, researchers have shown how synthetic biology can be used to solve a conundrum in cancer immunotherapy: Immunotherapy-related approaches focused on killing tumor cells in a wa
-
Clin Cancer Res: nivolumab in combination with temozolomide for neuroendocrine tumors
Time of Update: 2022-10-31
This is a non-randomized, multi-cohort, single-center Phase 2 trial that enrolled patients with advanced NEN and relapsed/metastatic small cell lung cancer to be treated with nivolumab (480 mg/4 weeks) plus temozolomide (150 mg/m2 orally, days 1-5/28) until disease progression or intolerable toxicity.
-
European Radiology: This MRI manifestation enables noninvasive evaluation of axillary lymph nodes in patients with early-stage breast cancer
Time of Update: 2022-10-31
A main cohort; B Verify the queueThis study showed that MRI of tumor-associated mammary edema can be used as an important imaging predictive feature to improve the prediction performance of pathological axillary lymph node load in patients with early-stage breast cancer, and further assist in the evaluation and implementation of preoperative treatment plans.
-
ESMO is unstoppable in the field to hit the ADC, and a new generation is imminent
Time of Update: 2022-10-03
The study showed that ZW49 has a manageable safety profile with encouraging antitumor activity in HER2-positive cancer patients receiving multi-line therapy.
The study showed that ZW49 has a manageable safety profile with encouraging antitumor activity in HER2-positive cancer patients receiving multi-line therapy.
-
A summary of the top guidelines for the first half of the infectious disease department, click to glance
Time of Update: 2022-09-08
cn/guideline/24870Recommended Reading:Glucocorticoids adjuvant therapy for tuberculosis, see the latest expert consensus!2022 JSC/JSTDM Clinical Practice Guidelines: Pharmacological Monitoring of TeicoplaninTicoplanin is a glycopeptide antibiotic that has a good effect on methicillin-resistant infections caused by Staphylococcus aureus (MRSA) and has been widely used in the treatment of PEOPLEA-infected patients due to the low risk of adverse effects of this drug.
-
Under the tide of acquisitions in the pharmaceutical industry, leading companies are accelerating their integration
Time of Update: 2022-08-15
It is understood that the acquisition will help Chutian Technology to expand its product series; at the same time, it will further strengthen the company's competitiveness in the field of pharmaceutical equipment, and the layout of multiple industrial chains will enhance the ability to resist risks and sustainable development .
-
Express AstraZeneca/Daiichi Sankyo's blockbuster ADC won the 5th breakthrough therapy designation for the treatment of HER2 low-expressing breast cancer
Time of Update: 2022-05-31
In DESTINY-Breast04, Enhertu provided a clinically meaningful survival benefit in patients with metastatic breast cancer with low HER2 expression .
” Reference: [1] ENHERTU® Granted Breakthrough Therapy Designation in US for Patients with HER2 Low Metastatic Breast Cancer.
-
Treat Biliary Cancer
Time of Update: 2022-05-01
/Patheon Manufacturing Services LLC injection ZW25 is planned to be included in the breakthrough therapy category .
ZW25 for injection as a single agent for the treatment of HER2-positive locally advanced unresectable or metastatic biliary tract cancer (BTC) that has failed previous systemic chemotherapy .
-
Lower odds of pregnancy and childbirth after single ovary IVF
Time of Update: 2022-04-26
"Our meta-study shows that women with only one ovary are less likely to have IVF success than women with both ovaries intact," says Karolinska Karolinska Institutet, Associate Professor, Department of Oncology Pathology, Karolinska Institutet said Kenny Rodriguez-Wallberg, a consultant at the University Hospital of Cardiff .
-
JAMA Dermatol: Does Spironolactone Really Cause Increased Cancer Risk
Time of Update: 2022-04-22
Given this official warning and uncertainty about the potential link between spironolactone use and cancer, the aim of this study was to conduct a systematic review and meta-analysis to synthesize the evidence on cancer risk from spironolactone use .
-
Tongji University and other places issued a paper: A new method for non-invasive screening of cervical lesions with cross-modal fusion
Time of Update: 2022-01-27
Recently, associate researcher Xia Wei of Suzhou Institute of Biomedical Engineering Technology, Chinese Academy of Sciences proposed a new method for non-invasive screening of cervical lesions by cross-modal fusion of cytology examination, HPV detection and colposcopy image examination results (as shown in Figure 1).
-
Nature Sub-Journal: Fighting with Poison
Time of Update: 2022-01-10
After specifically knocking out Scn10a-positive DRG or ANTXR2 on peripheral somatosensory neurons, intrathecal injection of edema toxin did not cause analgesic effects .
In summary, this article reveals that the receptor ANTXR2, which is enriched in DRG expression, mediates the analgesic effect of anthrax toxin .
-
Gastroenterology: How pancreatic injury causes cancer to form
Time of Update: 2021-11-14
Researchers from Vanderbilt University and the Salk Institute for Biological Research in the United States have recently discovered through single-cell transcriptomics analysis that acinar cells in the pancreas can form new cell types to reduce damage, but they are more likely to be in the presence of mutations.
